POULVAC MAREK HVT
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
23-06-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
MAREK HVT STRAIN F#126
Available from:
Pfizer Healthcare Ireland
ATC code:
QI01AD03
Pharmaceutical form:
Powder for reconstitution
Therapeutic group:
Immunological - Live Vaccine
Therapeutic area:
Fowl - Chicken
Authorization date:
2010-05-14
Summary of Product characteristics
IRISH MEDICINES BOARD ACT 1995
EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (NO. 2) REGULATIONS 2007
(S.I. NO. 786 OF 2007)
10019/178/001
Case No: 7007814
Transferred from 10861/061/001.
The Irish Medicines Board in exercise of the powers conferred on it by the Animal Remedies (No. 2) Regulations (S.I. No. 786 of 2007) hereby
grants to: PFIZER HEALTHCARE IRELAND
RINGASKIDDY, CO. CORK, IRELAND
an authorisation, subject to the provisions of the said Regulations and the general conditions of the attached authorisation, in respect of the
Veterinary Medicinal Product:
POULVAC MAREK HVT
The particulars of which are set out in Part 1 and Part 2 of the said Schedule. The authorisation is also subject to any special conditions as may
be specified in the said schedule.
The authorisation,unless revoked, shall continue in force from 14/05/2010.
Signed on behalf of the Irish Medicines Board
________________
A person authorised in that behalf by the said Board.
(NOTE: This authorisation replaces any previous authorisation in respect of this product which is now null and void.)
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 27/05/2010_
_CRN 7007814_
_page number: 1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Poulvac Marek HVT.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Powder for reconstitution for solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Day old chickens.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of chickens to reduce lesions of Marek’s Disease.
The onset of immunity occurs two weeks after vaccination.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not vaccinate diseased chic
Read the complete document
